Syncona launches new gene therapy player Purespring, spun out of the University of Bristol, with a roughly $60M Series A

Max Gelman

Senior Editor

Longtime UK life sciences investor Syncona has a new gene therapy outfit, one that the firm says is one of the first ever to focus on kidney disorders.

Syncona is launching Purespring Therapeutics with a £45 million Series A, or just shy of $60 million, in the hopes it can deliver on a new class of AAV gene therapies for chronic kidney diseases. Purespring is being spun out from the University of Bristol in the UK, based on the work of Moin Saleem, a professor for pediatric renal medicine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Syncona launches new gene therapy player Purespring, spun out of the University of Bristol, with a roughly $60M Series A

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Sage focuses on successful launch of postpartum depression drug

Syn­cona launch­es new gene ther­a­py play­er Pure­spring, spun out of the Uni­ver­si­ty of Bris­tol, with a rough­ly $60M Se­ries A

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Syncona launches new gene therapy player Purespring, spun out of the University of Bristol, with a roughly $60M Series A